Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Prescription, Nonprescription and Orphan Drugs01:02

Prescription, Nonprescription and Orphan Drugs

Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
FDA Approved Drugs: Changes to Approved Drugs01:26

FDA Approved Drugs: Changes to Approved Drugs

Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
Drug Dosage Regimen: Overview01:15

Drug Dosage Regimen: Overview

A drug dosage regimen describes the specific instructions and schedule for administering a drug to a patient. It considers factors such as drug dosage, frequency, route of administration, and duration of treatment. Designing an appropriate dosage regimen for a patient aims to achieve a target drug concentration at the site of action.
Typically, the starting dose and dosing interval are guided by the manufacturer's recommendations based on clinical trials conducted during and after drug...
Drug Products: Biologics, Biosimilars and Interchangeables01:28

Drug Products: Biologics, Biosimilars and Interchangeables

Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Findings of Research Misconduct.

Federal register·2026
Same journal

Findings of Research Misconduct.

Federal register·2026
Same journal

Findings of Research Misconduct.

Federal register·2026
Same journal

Findings of Research Misconduct.

Federal register·2025
Same journal

Findings of Research Misconduct.

Federal register·2025
Same journal

Findings of Research Misconduct.

Federal register·2024

Related Experiment Video

Updated: Jun 12, 2026

Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode
03:49

Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode

Published on: October 11, 2024

Copayments for medications. Final rule.

    Federal Register
    |June 8, 2010
    PubMed
    Summary

    The Department of Veterans Affairs (VA) finalized a rule freezing outpatient medication copayments until June 30, 2010. This action impacts how copayments are adjusted based on the Medical Consumer Price Index (CPI-P).

    Area of Science:

    • Health Policy
    • Pharmaceutical Economics
    • Public Health Administration

    Background:

    • Department of Veterans Affairs (VA) regulations mandate copayment adjustments for outpatient medications.
    • Copayment increases are typically tied to the prescription drug component of the Medical Consumer Price Index (CPI-P).
    • Annual maximum copayment amounts are also subject to adjustments based on individual copayment changes.

    Purpose of the Study:

    • To affirm as final an interim final rule regarding VA outpatient medication copayments.
    • To establish a specific period (through June 30, 2010) during which copayments were frozen.
    • To clarify the regulatory framework for future copayment adjustments.

    Main Methods:

    • Regulatory review and finalization of an interim rule.

    More Related Videos

    Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
    06:08

    Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

    Published on: March 11, 2017

    Related Experiment Videos

    Last Updated: Jun 12, 2026

    Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode
    03:49

    Enhanced Cochlear Coverage and Hearing Preservation in High-Frequency Hearing Loss via Electric Acoustic Stimulation with Longer Electrode

    Published on: October 11, 2024

    Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump
    06:08

    Evaluation of Drug Sorption to PVC- and Non-PVC-based Tubes in Administration Sets Using a Pump

    Published on: March 11, 2017

  • Analysis of existing VA regulations concerning medication copayments.
  • Consideration of the impact of the Medical Consumer Price Index (CPI-P) on pharmaceutical costs.
  • Main Results:

    • The interim final rule freezing copayments through June 30, 2010, was affirmed as final.
    • The established freeze superseded the standard adjustment mechanism based on CPI-P during the specified period.
    • The rule maintained the linkage between copayment increases and the CPI-P for periods beyond the freeze.

    Conclusions:

    • The VA implemented a temporary freeze on outpatient medication copayments to mitigate cost increases for beneficiaries.
    • This regulatory action highlights the VA's approach to managing pharmaceutical costs and patient financial burdens.
    • The finalized rule provides regulatory certainty regarding copayment policies for a defined period.